The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies (REMS), a ...

US FDA approves label updates for Bristol Myers’ CAR T cell therapies, Breyanzi for LBCL & lymphomas and Abecma for multiple myeloma: Princeton, New Jersey Saturday, June 28, 20 ...

These five well-run companies with stocks that yield at least 5% have strong dividend coverage and look like timely buys now.

The U.S. Food and Drug Administration (FDA) has removed the Risk Evaluation and Mitigation Strategies (REMS) requirement for all currently approved CAR-T cell therapies, a move expected to improve ...

Investors now have access to new options contracts for Bristol Myers Squibb expiring August 8th. A highlighted $45 put offers ...

Complete Bristol Myers Squibb Co. stock information by Barron's. View real-time BMY stock price and news, along with industry-best analysis.